Shire Offers €428 Million for Movetis To Expand Its GI Drug Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The J&J spin out, which raised more than €97 million in an IPO only eight months ago, would add to Shire's small but fast-growing gastrointestinal therapies franchise.